MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

607.0M

Vuru Grade

31.00/100

Current Price

$11.79
+0.02 (+0.17%)

Stability Price

$0.30
Overvalued by 97.42%

Company Metrics

  • 13.83 P/E
  • 13.40 P/S
  • 2.69 P/B
  • -2.126 EPS
  • -146.29% Cash ROIC
  • 11.20 Cash Ratio
  • 0.00 / N/A % Dividend
  • 482,683.00 Avg. Vol.
  • 51.48M Shares
  • 607.0M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals Heading For A Repeat
Seeking Alpha (registration) - Aug 5, 2014
On the cusp of another big biosimilar launch, Momenta would like to avoid another rapid decline. The company's deal with Novartis concerning generic Copaxone -- Teva's (NYSE:TEVA) popular multiple sclerosis therapy -- has a couple features that could ...
Momenta Pharmaceuticals Announces Abbreviated New Drug Application for ...
MarketWatch - Aug 28, 2014
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA.
Teva's Patent Problems Continue - Bidness ETC
Momenta-Sandozs Generic Copaxone Accepted for Review by FDA - Zacks.com
Momenta Pharmaceuticals President Craig A. Wheeler Sells 2209 Shares (MNTA)
WKRB News - Aug 27, 2014
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Thursday, July 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.05.
Technical Roundup on Biotech Stocks -- Medivation, Ironwood Pharma ...
Wall Street Journal - Aug 12, 2014
Shares in Momenta Pharmaceuticals Inc. have advanced 3.36% in the previous three trading sessions. However, the company's shares are down 2.90% in the last one month and 35.58% on YTD basis.
Insider Selling: Momenta Pharmaceuticals Director Sells 3721 Shares of Stock ...
WKRB News - Aug 15, 2014
Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 0.26% on Friday, hitting $11.65. 188,459 shares of the company's stock traded hands. Momenta Pharmaceuticals has a 52-week low of $9.85 and a 52-week high of $19.90. The stock's 50-day moving ...
Momenta Pharmaceuticals President Sells $25293 in Stock (MNTA)
sleekmoney - Aug 28, 2014
The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter last year, the company posted ($0.57) earnings per share. Momenta Pharmaceuticals's revenue was up 151.1% ...
Stocks in the News: FuelCell Energy Inc (NASDAQ:FCEL), Lululemon Athletica ... - Financial Wired (registration)
Insider Selling: Bennett M. Shapiro Sells 3722 Shares of Momenta ...
WKRB News - Aug 20, 2014
Momenta Pharmaceuticals logo Momenta Pharmaceuticals (NASDAQ:MNTA) Director Bennett M. Shapiro sold 3,722 shares of the company's stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of ...
Traders Are Watching : Exa Corporation (NASDAQ:EXA), Microchip Technology ... - WallStreet Scope
Momenta Pharmaceuticals President Unloads $25293 in Stock (MNTA)
Mideast Time - Aug 26, 2014
261,742 shares of the company's stock traded hands. Momenta Pharmaceuticals has a 52 week low of $9.85 and a 52 week high of $19.90.
Moving Stocks : TransCanada Corp. (NYSE:TRP), The Nasdaq OMX Group ... - WallStreet Scope
Insider Selling: Bennett M. Shapiro Unloads 3721 Shares of Momenta ...
Ticker Report - Aug 17, 2014
Momenta Pharmaceuticals logo Momenta Pharmaceuticals (NASDAQ:MNTA) Director Bennett M. Shapiro unloaded 3,721 shares of the company's stock on the open market in a transaction that occurred on Wednesday, August 13th. The stock was sold at an ...
Momenta Pharmaceuticals Director Sells $44652 in Stock (MNTA) - Mideast Time
Momenta Pharmaceuticals Director Sells $44664 in Stock (MNTA) - Watch List News (press release)
Don't Miss: Ford Motor Co. (NYSE:F), Momenta Pharmaceuticals Inc. (NASDAQ ...
Crazy Joys - Aug 4, 2014
Momenta Pharmaceuticals (NASDAQ:MNTA) posted its quarterly earnings results on Thursday. The company reported ($0.51) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.46) by $0.05.